Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
According to a media release issued on Thursday this week by Molecular Insight Pharmaceuticals, Inc. (MIP), an investigational imaging agent known as Trofex™ (a.k.a, 123I-MIP-1072) may offer a new opportunity to identify the presence of early signs of metastatic prostate cancer in the prostate bed, soft tissues, and bone within 4 hours after injection.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: 123I-MIP-1072, agent, imaging, PMSA, Trofex | 2 Comments »
We have previously reported on studies related to the possibility that the xenotropic murine leukemia virus–related (XMRV) virus is in some way involved with risk for prostate cancer in some patients.
Filed under: Diagnosis, Risk | Tagged: risk, XMRV | Leave a Comment »
Initiation of androgen deprivation therapy (ADT) has long been associated with the loss of lean muscle mass and a gain in mass of fatty tissue, leading toward an overall weight gain over time. However, data from the “real world” on the degree to which ADT actually affects body mass has been very limited.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation therapy, gain, loss, weight | 4 Comments »
A new study reports on retrospective analysis of data from a series of 218 patients diagnosed between 1991 and 2005 with localized prostate cancer and who were managed using a “watchful waiting” (as opposed to an active surveillance) strategy at the Massachusetts General Hospital (MGH).
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: localized, outcome, risk, watchful waiting | 4 Comments »
If you just read the media reports (for example, from Reuters, from the BBC or from The Daily Telegraph) you might get the idea that a new urine-based test for a protein called MSMB is vastly better at detecting prostate cancer than the PSA test. Sorry, but that is not actually the case at all.
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: gene, microseminoprotein-β, MSMB, risk | 1 Comment »
There really are remarkably few published data from well-constructed studies of patient satisfaction following treatment for prostate cancer presumed to be localized at the time of treatment.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: outcome, radical prostatectomy, satisfaction, Treatment | 11 Comments »
Several years ago, Bolla et al. planned and carried out the major European trial showing that external beam radiation therapy with 3 years of androgen deprivation therapy (ADT, using goserelin acetate) extended the prostate cancer-specific and the overall survival of patients with high-risk localized prostate cancer as compared to radiation alone.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: 3D-CRT, ADT, androgen deprivation therapy, chemohormonal, docetaxel, radiation | 2 Comments »
According to a media release from Myriad Genetics, the company’s investigational genetic test (Prolaris™) can accurately predict prostate cancer-specific mortality at 10 years in men known to have clinically localized prostate cancer.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: cancer-specific, genes, mortality, prognosis, PROLARIS, test | 4 Comments »
Relatively few data have been published on the pathological outcomes of patients initially diagnosed with atypical small acinar proliferation (ASAP), i.e., atypical glands suspicious but not diagnostic for prostate cancer, who are diagnosed with prostate cancer on re-biopsy and then treated by radical prostatectomy.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: ASAP, Diagnosis, pathology, radical prostatectomy, RP | Leave a Comment »
As previously reported, a “compassionate use” study of abiraterone actetate is expected to start shortly (first in the USA and then in other countries).
Filed under: Drugs in development, Management, Treatment | 5 Comments »
A new report from Laurence Klotz’s group in Toronto basically tells us that no currently identified PSA-based “trigger” can be used alone to determine when a man on active surveillance should be switched over to active treatment.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active surveillance, PSA, Treatment, trigger | 3 Comments »
According to a media release last Thursday and a report on Medical News Today, the Agency for Healthcare Research and Quality (AHRQ) has awarded a large grant to the Vandebilt-Ingram Cancer Center) for study of the comparative effectiveness of differing types of first-line treatment for localized prostate cancer.
Filed under: Uncategorized | Tagged: comparative effectiveness, radiation, surgery | 8 Comments »
A recent study reported in the Journal of Clinical Endocrinology and Metabolism has been receiving a good deal of media attention, although its immediate clinical importance wouldn’t appear to be particularly high.
Filed under: Uncategorized | Tagged: ADT, androgen deprivation therapy, bone, density, fragility | 2 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site